

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/262146813>

Probing the aurone scaffold against *Plasmodium falciparum*: Design, synthesis and antimalarial activity

ARTICLE · JANUARY 2014

CITATION

1

READS

42

12 AUTHORS, INCLUDING:



Fatima Nogueira

Institute of Hygiene and Tropical Medicine

38 PUBLICATIONS 370 CITATIONS

SEE PROFILE



Thomas Hanscheid

University of Lisbon

79 PUBLICATIONS 1,187 CITATIONS

SEE PROFILE



Rita C Guedes

University of Lisbon

69 PUBLICATIONS 907 CITATIONS

SEE PROFILE



Rui Moreira

University of Lisbon

160 PUBLICATIONS 1,843 CITATIONS

SEE PROFILE



Original article

Probing the aurone scaffold against *Plasmodium falciparum*: Design, synthesis and antimalarial activity

Marta P. Carrasco^a, Ana S. Newton^a, Lúcia Gonçalves^a, Ana Góis^b, Marta Machado^c, Jiri Gut^d, Fátima Nogueira^c, Thomas Hänscheid^b, Rita C. Guedes^a, Daniel J.V.A. dos Santos^{a,1}, Philip J. Rosenthal^d, Rui Moreira^{a,*}

^a Instituto de Investigação do Medicamento (iMed.Ulisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto 1649-003 Lisboa, Portugal

^b Unidade de Microbiologia Molecular e Infecção, Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, 1649-028 Lisboa, Portugal

^c Centro de Malária e outras Doenças Tropicais, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, 1349-008 Lisboa, Portugal

^d Department of Medicine, San Francisco General Hospital, University of California, San Francisco, Box 0811, San Francisco, CA 94143, USA

ARTICLE INFO

Article history:

Received 9 November 2013

Received in revised form

24 April 2014

Accepted 25 April 2014

Available online 28 April 2014

Keywords:

Malaria

Plasmodium falciparum

Aurones

Cross-coupling reactions

ABSTRACT

A library comprising 44 diversely substituted aurones derivatives was synthesized by straightforward aldol condensation reactions of benzofuranones and the appropriately substituted benzaldehydes. Microwave enhanced synthesis using palladium catalyzed protocols was introduced as a powerful strategy for extending the chemical space around the aurone scaffold. Additionally, Mannich-base derivatives, containing a 7-aminomethyl-6-hydroxy substitution pattern at ring A, were also prepared. Screening against the chloroquine resistant *Plasmodium falciparum* W2 strain identified novel aurones with IC₅₀ values in the low micromolar range. The most potent compounds contained a basic moiety, with the ability to accumulate in acidic digestive vacuole of the malaria parasite. However, none of those aurones revealed significant activity against hemozoin formation and falcipain-2, two validated targets expressed during the blood stage of *P. falciparum* infection and functional in digestive vacuole of the parasite. Overall, this study highlight (i) the usefulness of aurones as platforms for synthetic procedures using palladium catalyzed protocols to rapidly deliver lead compounds for further optimization and (ii) the potential of novel aurone derivatives as promising antimalarial compounds.

© 2014 Elsevier Masson SAS. All rights reserved.

1. Introduction

Malaria remains a critical global health problem, with terrible social and economic consequences in countries where this disease is endemic. The problem is exacerbated by the emergence and spread of parasites that are resistant to well-established antimalarial drugs [1]. For that reason, development of new, effective, nontoxic, and affordable antimalarial drugs is a high priority in medicinal chemistry [2,3]. To achieve this goal, the most important strategies include not only rational drug design but also exploitation of natural products either as a source of antiparasitic agents or as an inspiration to design novel molecular scaffolds [4,5]. Therefore, the evaluation of the antiparasitic activity of plant extracts or

compounds isolated from natural sources represents a valuable approach for the design and development of new drugs.

Aurones, 2-benzylidenebenzofuran-3-(2H)-ones (Fig. 1), are structural isomers of flavones that contain an exocyclic carbon–carbon double bond bridging the benzofuranone and phenyl rings [6,7]. The therapeutic potential of aurones has been highlighted with recent studies that revealed their anticancer [8–13], antimicrobial [14], antiparasitic [15–18], antiviral [19], and anti-inflammatory [14,20] activities. In addition, aurones can act as modulators of ABC drug transporters [21–25] and present inhibitory activity against acetylcholinesterase [26] and MAO-B [27].

The antimalarial potential of aurones was first reported by Kayser et al. [16]. Moreover, several naturally occurring aurones were synthesized and tested for their ability to inhibit erythrocytic stages of *Plasmodium falciparum*. Some of these compounds exhibited antiplasmodial activity in the micromolar range, and they showed no cytotoxicity against mammalian tumor cell lines. More recently, Souard et al. [18] showed that a series of synthetic aurones

* Corresponding author.

E-mail address: rmoreira@ff.ul.pt (R. Moreira).

¹ Present address: REQUIMTE, Department of Chemistry & Biochemistry, Faculty of Sciences, University of Porto, R. do Campo Alegre, 4169-007 Porto, Portugal.





Fig. 1. General structure of aurones.

exhibited IC_{50} values under 5 μM against *P. falciparum* without toxicity against human cells.

Palladium-catalyzed reactions provide an excellent platform for compound library extension due to the wide range of transformations mediated by palladium [28]. Most of the aurone-based libraries already screened against *P. falciparum* were inspired by naturally occurring aurones, typically containing hydroxy, methoxy or acetoxy groups at different positions of this scaffold. Herein we present the synthesis and screening of a library of novel aurones, **1–7** (Tables 1–4), designed to probe the chemical space around this scaffold. Many of the target compounds were obtained through Suzuki–Miyaura and Buchwald–Hartwig cross-coupling reactions. Moreover, taking into account recent data suggesting antimalarial activity of aurone–Mannich base derivatives [29], some compounds were also obtained via the introduction of different aliphatic amines in the benzofuranone ring. All compounds were evaluated for their activity against a chloroquine-resistant strain of *P. falciparum* and for their cytotoxicity against human cancer cell lines. To gain insights into the mechanism of action of this class of compounds, additional studies were performed to evaluate the

Table 2

Structure, $clogP$ values and yields for the synthesis (final step) of aurones **4**.



Compound	R^3	$cLogP^a$	Yield %
4a	H	3.09	62
4b	2,4-F	3.62	95
4c	2,4-Cl	4.55	59
4d	3,4,5-OMe	2.93	99

^a $clogP$ values calculated using the AlogPS 2.1 software (<http://www.vcclab.org/lab/alogsps/>); reference [56].

ability of selected aurones to inhibit hemozoin formation and falcipain-2, a cysteine protease from *P. falciparum*, and to address the possibility of synergism when combined with chloroquine.

2. Results and discussion

2.1. Chemistry

A total of 44 aurone derivatives with a wide range of substituents in ring A and B were synthesized to explore the potential of this scaffold as a platform to design new antimalarial agents (Tables 1–4).


Compounds **1a–h**, **2j–k** and **4a–d** were synthesized from commercially available benzofuran-3(2H)-one, **8**, or 7-methoxy-3(2H)-benzofuranone, **9**, which were reacted with appropriately substituted benzaldehydes in the presence of neutral alumina [30], as shown in Scheme 1a.

However, this method failed to provide the 6-hydroxy aurones **5a–g** in reasonable yields. In contrast, base-catalyzed aldol condensation of 6-hydroxy-3(2H)-benzofuranone, **10**, with benzaldehydes afforded aurones **5a–d** in good yield (Scheme 1A), while **5e–g** were obtained under acidic conditions, in the presence of glacial acetic acid and hydrochloric acid. The aldehydes required for aurones **5f–g** were synthesized from 4-fluorobenzonitrile and the appropriate phenol, and via the Weinreb amides **13a,b**, as described in Scheme 1B.

Compounds **2a–g**, **3a–g** and **6a–c** were obtained through a standard Suzuki–Miyaura cross-coupling reaction in the presence

Table 3

Structure, $clogP$ values and yields for the synthesis (final step) of aurones **5**.




Compound	R^3	$cLogP^a$	Yield %
5a	H	3.02	99
5b	2,4-F	3.35	98
5c	2,4-Cl	4.25	99
5d	3,4,5-OMe	2.60	98
5e	NMe ₂	3.17	71
5f	4-(OC ₆ H ₄ -4'-Me)	5.27	51
5g	4-(OC ₆ H ₄ -4'-Cl)	5.13	84

^a $clogP$ values calculated using the AlogPS 2.1 software (<http://www.vcclab.org/lab/alogsps/>); reference [56].

Table 1


Structure, $clogP$ values and yields for the synthesis (final step) of aurones **1–3**.







Compound	R^3	$cLogP^a$	Yield %
1a	H	3.39	41
1b	2-Br	4.12	55
1c	3-Br	4.13	54
1d	4-Br	4.12	56
1e	2,4-F	3.72	30
1f	2,4-Cl	4.60	81
1g	3,4,5-OMe	3.01	64
1h	4-NMe ₂	3.51	49
2a	4-Ph	5.06	77
2b	4-(C ₆ H ₄ -4'-F)	5.21	66
2c	4-(C ₆ H ₄ -4'-Cl)	5.65	64
2d	4-(C ₆ H ₄ -4'-CHO)	4.70	83
2e	4-Bn	5.24	70
2f	4-(3'-Quinoline)	5.16	87
2g	4-[5'-(Pyridin-2'-NH ₂)]	3.69	98
2h	4-(NHPh)	4.83	71
2i	4-(NHBn)	4.62	49
2j	4-(OC ₆ H ₄ -4'-Me)	5.40	33
2k	4-(OC ₆ H ₄ -4'-Cl)	5.51	51
3a	3-Ph	5.05	71
3b	3-(C ₆ H ₄ -4'-F)	5.21	65
3c	3-(C ₆ H ₄ -4'-Cl)	5.65	51
3d	3-(C ₆ H ₄ -4'-CHO)	4.70	63
3e	3-Bn	5.24	49
3f	3-(3'-Quinoline)	5.16	68
3g	3-[5'-(Pyridin-2'-NH ₂)]	3.69	76

^a $clogP$ values calculated using the AlogPS 2.1 software (<http://www.vcclab.org/lab/alogsps/>); reference [56].

Table 4
Structure, clogP values and yields for the synthesis (final step) of aurones **6**–**7**.



Compound	R ¹	R ²	cLogP ^a	Yield %
6a	Ph	H	5.24	78
6b	C ₆ H ₄ -4'-F	H	5.05	66
6c	5'-(Pyridin-2'-NH ₂)	H	5.20	99
7a	OH		2.55	61
7b	OH		3.73	63
7c	OH		2.47	54
7d	OH		3.55	29

^a clogP values calculated using the AlogPS 2.1 software (<http://www.vcclab.org/lab/alogs/>); reference [56].

of Pd(PPh₃)₂Cl₂ as catalyst, as described by Liu et al. [31] (Scheme 2). Performing the cross-coupling reactions on starting materials **1d** and **1c** afforded aurones **2a–g** and **3a–g**, respectively, in moderate to very good yields. The synthesis of compounds **6a–c** was

accomplished through the Suzuki–Miyaura cross-coupling reaction of triflate **15**, obtained from the starting material **10**. Aurones **2h** and **2i** were prepared via the Buchwald–Hartwig cross-coupling reaction following the Fitzmaurice et al. procedure [28]. Starting material **1d** was reacted with the appropriate amine in the presence of Pd₂(dba)₃, (R)-BINAP, and NaOtBu in microwave conditions to afford **2h** and **2i** were in moderate yields (Scheme 2).


Finally, the Mannich-base derivatives **7a–d** were synthesized in moderate yields by reacting the starting material **5a** with the appropriate aliphatic secondary amine in aqueous formaldehyde (Scheme 3).

The stereochemistry of the carbon–carbon double bond in aurones **1–7** was assigned as having the (Z)-configuration based mainly on ¹³C chemical shifts for the exocyclic (β) carbon atom. The ¹³C NMR data obtained for aurones reveal that the chemical shift for the exocyclic carbon range from 108 to 112 ppm, in line with the values reported for (Z)-aurones [32,33], the thermodynamically more stable isomer [34]. In contrast, the ¹³C chemical shifts for the exocyclic carbon in (E)-aurones are usually observed at significantly higher frequency (ca. 120–130 ppm) [17]. Information from the ¹H NMR spectra was less informative, as the ¹H chemical shifts for the β-hydrogen atoms in most of aurones **1–7** ranged from 6.7 to 7.1 ppm, consistent with reported values for (Z)-aurones (ca. 6.7 ppm) and (E)-aurones (ca. 7.2 ppm) [32–33]. This ambiguity in ¹H chemical shifts values might be ascribed to the electronic properties of substituents at ring B [18].


2.2. Biological evaluation

2.2.1. Activity against *P. falciparum*


All compounds were assayed for their antiplasmodial activity against the chloroquine-resistant *P. falciparum* W2 strain and for their toxicity against Human Embryonic Kidney 293T cells. The data presented in Table 5 reveals that 21 aurones displayed relevant antiplasmodial activity, with IC₅₀ values ranging from 1.2 to 9.9 μM. In addition, aurones **1–7** presented negligible cytotoxicity, with



Scheme 1. Reagents and conditions: (a) **8** or **9**, Al₂O₃, MeOH, reflux under N₂, 24 h; (b) **10**, NaOH (1 M), H₂O, RT, 4 h (for **5a** to **5d**); (c) **10**, glacial AcOH, HCl (cat), RT, 4 h (for **5e** to **5g**); (d) substituted phenol, Na₂CO₃, dry DMF, reflux, 24 h; (e) H₂O₂ (30%), KOH, MeOH, EtOH, reflux, 5 h; (f) N,O-dimethylhydroxylamine, TEA, TBUT, dry DMF, RT, overnight; (g) LiAlH₄, dry THF, −5 °C. R³ is according to Tables 1–3.



Scheme 2. Reactions and conditions: (a) **1c**, **1d**, or **15**, $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$, Na_2CO_3 (1 M), 1,4-dioxane, 100°C , 3 h; (b) **1d**, $\text{Pd}_2(\text{dba})_3$, (R)-BINAP, NaO^tBu , dry toluene, 100°C , 15 min, MW. R^3 is according to Tables 1–3.



Scheme 3. Reactions and conditions: (a) aliphatic amine, formaldehyde solution, EtOH, reflux, 5 h.

EC_{50} values against cultured human cells ranging from 68 to ≥ 100 μM . In general, most of the compounds presented selectivity indices ($\text{SI} = \text{EC}_{50}(\text{HEK293T})/\text{IC}_{50}(\text{W2})$) higher than 10, indicating that aurones are selective and nontoxic antiparasmodial agents.

Inspection of the data in Table 5 shows that aurones containing basic moieties, specifically 3-(2'-amino)pyridine (**2g**, **3g**, **6c**), 3-quinoline (**2f**, **3f**), and Mannich-bases, (**7a–d**) generally present improved antiparasmodial activity when compared to their non-basic counterparts. For example, the Mannich-base derivatives, **7a–d**, are significantly more active than their parent compound **5a**, an observation in line to that reported for similar Mannich-bases in clinical use such as amodiaquine and pyronaridine [35]. The basic moiety can exert its beneficial effect on activity independently of its localization in the aurone scaffold. For example, compound **6c**, which contains a 2-aminopyridine moiety in ring A, is equipotent to its counterparts **2g** and **3g**, which contain the basic moiety at C-4 and C-3 of ring B, respectively. A similar effect was reported for chalcones, where substitution with a quinoline moiety at ring A or ring B provided compounds with antiparasmodial activity in the low micromolar range [36].

Aurones containing a second aromatic or benzyl moiety at C-3 of ring B were shown to be more potent than their C-4 substituted counterparts (compounds **3a**, **3b** and **3e** versus **2a**, **2b** and **2e**, respectively). Replacement of the benzyl group at ring B by its anilino or phenoxy isosters had a detrimental effect on antiparasmodial activity (**2e** versus **2h** and **2j,k**). The same trend in activity was observed when the benzylamine moiety at C-4 of ring B was replaced by its aniline counterpart (**2i** versus **2h**). In general, derivatives containing an hydroxyl or methoxy group at ring A were poorly active, independently of substituents at ring B, with exception of the 7-methoxy derivative **4c**, which presented an IC_{50} value of 4.8 μM .

Overall, these results indicate that introduction of a basic moiety to the aurone scaffold can improve antiparasmodial activity. Aurone **7b** emerged as the most promising compound, with an IC_{50} value of 1.2 μM and an excellent selectivity index $\text{SI} > 85$. Since insight into the mechanism of action is helpful for drug development, we screened aurones against two validated targets expressed during the blood stage of *P. falciparum* infection: hemozoin formation and falcipain-2.

2.2.2. Screening against targets localized in the parasite digestive vacuole

Plasmodium parasites dispose the free, toxic heme that results from digestion of host erythrocyte hemoglobin by crystallizing it into hemozoin crystals. Heme detoxification takes place in the acidic digestive vacuole (DV) of the parasite (pH 5.2), and is believed to be the target of several antimalarial drugs [37]. It was recently reported that Mannich-base derivatives of aurones might interfere with heme polymerization inside the DV of erythrocytic parasites [29]. Since there is strong evidence that pH trapping plays a role in the activity of basic antimalarials such as chloroquine, we assessed the possibility of the quinoline (**2f**, **3f**), 2-aminopyridine (**2g**, **3g**, **6c**) and Mannich-base aurone derivatives (**7a–d**) being trapped in the acidic DV, by calculating the vacuolar accumulation ratio (VAR) based on the pH-dependent distribution of these compounds between water and lipid (log D) (Table 6) [37]. We also determined the lipid accumulation ratio (LAR), which measures the expected ratio of compound that would concentrate within the lipid component within the DV [37].

As shown by the VAR values presented in Table 6, basic aurones have the potential to accumulate within the DV, with compound **7a** exhibiting a VAR value comparable to that of chloroquine, reflecting the predominance of its doubly positively charged form at pH 5.2.

Table 5

Antiplasmodial activity (IC₅₀) against the chloroquine-resistant *Plasmodium falciparum* W2 strain, cytotoxicity (EC₅₀) against Human Embryonic Kidney 293T cells and selectivity index (SI = EC₅₀/IC₅₀) for aurones **1–7**.

Compd	IC ₅₀ /μM	EC ₅₀ /μM	SI	Compd	IC ₅₀ /μM	EC ₅₀ /μM	SI	Compd	IC ₅₀ /μM	EC ₅₀ /μM	SI
1a	>10	>100	>10	2h	8.59	>100	>12	5a	>10	>100	>10
1b	>10	>100	>10	2i	5.00	>100	>20	5b	>10	>100	>10
1c	4.70	>100	>21	2j	>10	>100	>10	5c	>10	>100	>10
1d	3.21	>100	>31	2k	>10	>100	>10	5d	>10	>100	>10
1e	>10	>100	>10	3a	5.21	>100	>19	5e	>10	>100	>10
1f	>10	68	<6.8	3b	4.41	>100	>23	5f	5.84	95	>16
1g	>10	>100	>10	3c	>10	>100	>10	5g	9.88	12	>1
1h	7.99	>100	>13	3d	>10	>100	>10	6a	>10	>100	>10
2a	>10	>100	>10	3e	2.31	71	>31	6b	>10	>100	>10
2b	>10	>100	>10	3f	4.78	>100	>21	6c	3.03	>100	>33
2c	>10	>100	>10	3g	2.56	79	>31	7a	4.01	>100	>25
2d	>10	>100	>10	4a	>10	>100	>10	7b	1.18	>100	>85
2e	7.34	87	>12	4b	>10	>100	>10	7c	3.34	>100	>30
2f	6.59	>100	>15	4c	4.80	>100	>21	7d	3.47	>100	>29
2g	3.70	>100	>27	4d	>10	>100	>10	CQ	0.14	N.D.	N.D.

With exception of the piperazine Mannich-base **7a**, most of the basic aurones exhibit high LAR values, suggesting the preference of these compounds for a lipophilic environment. Consequently, upon entrance into the digestive food vacuole, the compounds could accumulate within the neutral lipid particles at the sight of hemozoin formation [38,39]. However, no clear correlation emerged between the pIC₅₀ values for antiplasmodial activity of compounds **2f–g**, **3f–g**, **6c**, **7a–d**, and their LAR or VAR values. Furthermore, none of these basic-aurones inhibited hemozoin formation at concentrations up to 1 mM, when assayed using a hemozoin-like crystal inhibition assay [40]. Overall, the VAR value obtained for these compounds show their ability to accumulate in the DV, and, as a result, this class of compounds may probably interact with other targets within this compartment (Table 6).

Aurones **1–6** were also screened for inhibition of cysteine protease from *P. falciparum*, falcipain-2, which is of particular interest as therapeutic target due to its role in parasite development [41]. Falcipain-2 localizes in the parasite's DV and plays a key role in the hydrolysis of host hemoglobin into amino acids essential to parasite growth [42]. Additionally, falcipain inhibitors that contain a Michael acceptor warhead [43] have been reported to block the development of cultured erythrocytic parasites and to cure mice infected with lethal malaria infections [44]. Although aurones are well known Michael acceptors [6], none of the aurones **1–6** inhibited falcipain-2 in concentrations up to 50 μM (data not shown). The only exception was compound **4c**, which showed to be a weak falcipain-2 inhibitor with an IC₅₀ value of 18.6 μM. The observation that falcipain-2 is inhibited only in the high μM range, suggests that aurone scaffold is not suitable for enzyme binding.

2.2.3. In vitro drug combination assay

Previous studies showed that aurone derivatives inhibit ABC transporters, a family of proteins involved in multidrug resistance [21–25]. Moreover, the importance of this type of transporters was already demonstrated for resistance of malaria parasites to chloroquine [45,46]. Therefore, we evaluated the antimalarial effects of compound **7c** combined with chloroquine by a modified fixed ratio isobologram method [47–50]. Isobologram analysis, based on calculation of the sum of fractional inhibitory concentration values (FICs = IC₅₀ of drug in the combination/IC₅₀ of drug when tested alone) or combination index (CI) [50] gives an indication of whether the interaction is antagonistic, additive or synergistic. Although there are no defined breakpoints for antimalarial combinations, a recent study defined synergism as CI < 0.9, additive effect as 0.90 ≤ CI < 1.10 and antagonism as CI ≥ 1.10 [51]. The CI value of 1.06 obtained for compound **7c** demonstrated an additive interaction between this compound and chloroquine (Fig. 2). Therefore, synergy of this class of compounds with chloroquine was not demonstrated.

3. Conclusions

Novel aurone derivatives with additional structural complexity and diversity were synthesized and screened against a chloroquine-resistant *P. falciparum* strain. We demonstrated that aurones provide a useful scaffold to generate novel bioactive compounds and that appropriate functionalization of the aurone scaffold yielded compounds with antiplasmodial activity in the low micromolar range and with low cytotoxicity. In particular, aurones containing basic moieties with capacity to protonate under weakly

Table 6

Physicochemical parameters for compounds selected compounds. cLogP values were calculated using AlogPS 2.1 software from Virtual Computational Chemistry Laboratory [56]. pK_a values were obtained from SPARC software [57], except when indicated. Values of logD, VAR and LAR were calculated using the equations available in Ref. [37].

Compd	clogP	pK _a ¹	pK _a ²	logD _{7.4}	logD _{5.2}	VAR	LAR	MIC/μM	IC ₅₀ /μM
2f	5.16	4.49 ^a	—	5.16	5.08	1.19	144366	ND	6.59
2g	3.69	6.14 ^b	—	3.67	2.70	9.20	4643	NI	3.70
3f	5.16	4.49 ^a	—	5.16	5.08	1.19	144,366	ND	4.78
3g	3.69	6.14 ^b	—	3.67	2.70	9.20	4643	NI	2.56
6c	5.20	6.14 ^b	—	5.18	4.21	9.20	150,233	NI	3.03
7a	2.55	8.50	7.78	1.02	−3.33	22,589	10.6	NI	4.01
7b	3.73	9.08	—	2.04	−0.15	155	110	NI	1.18
7c	2.47	6.46	—	2.42	1.19	17.2	265	NI	3.34
7d	3.55	9.15	—	1.79	−0.40	156	62.0	NI	3.47
CQ	7.72	10.18	8.38	0.92	−3.44	22749	8.25	125	0.14

NI: no inhibition of hemozoin-like crystal formation; ND: not determined.

^a Calculated from Ref. [58].

^b Calculated from Ref. [59].




Fig. 2. Isobologram showing the relationship between the FIC₅₀ of chloroquine and compound **7c** against *Plasmodium falciparum* Dd2 strain. Numbers on each plotted point correspond to the calculated combination index (CI) value for the utilized combination ratio.

acidic conditions (2-aminopyridine, Mannich-bases) emerged as the most active in this series. Our preliminary results indicate that the primary mechanism of action of these basic aurones does not involve inhibition of hemozoin formation. Furthermore, aurones **1–7** are only poorly inhibitors of falcipain-2, which is believed to operate in acidic DV of the parasite. However, the high VAR values obtained for the basic aurones indicate their ability to accumulate in the DV which may be related with their mode of action. Further studies are underway to unravel the antimalarial mechanism of this class of compounds. In conclusion, our results highlight the potential of the aurone scaffold for future antiplasmodial lead optimization.

4. Experimental

4.1. Chemistry

All reagents and solvents were obtained from commercial suppliers and were used without further purification. Melting points were determined using a Kofler camera Bock monoscope M and are uncorrected. Merck Silica Gel 60 F254 plates were used as analytical TLC and flash column chromatography was performed on Merck Silica Gel (200–400 mesh). ¹H and ¹³C NMR spectra were recorded on a Bruker 400 Ultra-Shield (400 MHz). ¹H and ¹³C chemical shifts are expressed in parts per million (ppm, δ) referenced to the solvent used and the proton coupling constants (*J*) in hertz. Proton coupling patterns were described as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), doublet of doublets (dd), and broad (br). Low-resolution mass spectra were recorded using a VG Quattro LCMS instruments. HR-ESI-MS were recorded on an ESI-TOF spectrometer (Biotof II Model, Bruker). Elemental analyses were performed using an EA 1110 CE Instruments automatic analyser. The microwave-assisted synthesis was performed in a CEM Corporation Discover[®] Labmate[™].

4.1.1. General procedure for the synthesis of aurones **1a–h**, **2j–k** and **4a–d**

To a solution of benzofuran-3(2H)-one (134 mg, 1 mmol) in dry methanol (20 mL) at room temperature was added the appropriate aldehyde (1.2 mmol) and Al₂O₃ (1 mmol). The mixture was refluxed, under N₂, for 48 h. After, the solvent was removed and the solid residue was dissolved in CH₂Cl₂. The organic layer was

washed with water, dried with anhydrous Na₂SO₄ and concentrated under reduced pressure to give the crude product.

4.1.1.1. (Z)-2-Benzylidenebenzofuran-3(2H)-one (1a). Purified by flash chromatography (Hexane/CH₂Cl₂ = 80:20). Obtained as yellow solid, yield 41%, mp 113–114 °C. ¹H NMR (400 MHz, CDCl₃) δ = 7.97–7.90 (m, 2H), 7.82 (dd, *J* = 7.6, 0.8 Hz, 1H), 7.66 (ddd, *J* = 8.5, 7.4, 1.4 Hz, 1H), 7.51–7.38 (m, 3H), 7.34 (d, *J* = 8.3 Hz, 1H), 7.23 (t, *J* = 7.5 Hz, 1H), 6.91 (s, 1H). ¹³C NMR (101 MHz, MeOD) δ = 186.22, 167.63, 138.77, 132.71, 132.09, 131.23, 130.04, 129.42, 125.38, 124.98, 122.52, 114.24, 114.15. Anal. Calcd. (C₁₅H₁₀O₂·0.15H₂O): C, 80.09; H, 4.62%. Found: C, 80.35; H, 4.97%.

4.1.1.2. (Z)-2-(2-Bromobenzylidene)benzofuran-3(2H)-one (1b). Purified by flash chromatography (Hexane/EtOAc = 95:5). Obtained as yellow solid, yield 55%, mp 169–171 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 8.32 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.85–7.79 (m, 3H), 7.59–7.56 (m, 2H), 7.40–7.33 (m, 2H), 7.07 (s, 1H). ¹³C NMR (101 MHz, DMSO-*d*₆): δ = 184.15, 166.14, 147.66, 138.55, 133.87, 132.47, 132.09, 131.51, 128.88, 126.06, 125.03, 124.78, 121.02, 113.78, 109.23. Anal. Calcd. (C₁₅H₉BrO₂): C, 59.82; H, 3.02%. Found: C, 59.67; H, 3.13%.

4.1.1.3. (Z)-2-(3-Bromobenzylidene)benzofuran-3(2H)-one (1c). Purified by flash chromatography (Hexane/EtOAc = 95:5). Obtained as yellow solid, yield 54%, mp 123–124 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 8.18 (s, 1H), 8.03 (d, *J* = 7.9 Hz, 1H), 7.83–7.81 (m, 2H), 7.66 (d, *J* = 7.9 Hz, 1H), 7.61 (d, *J* = 8.2 Hz, 1H), 7.48 (t, *J* = 7.9 Hz, 1H), 7.34 (t, *J* = 8.2 Hz, 1H), 6.96 (s, 1H). ¹³C NMR (101 MHz, DMSO-*d*₆): δ = 184.15, 166.02, 147.31, 138.42, 134.81, 133.88, 133.03, 131.56, 130.59, 124.90, 124.67, 122.68, 121.14, 113.82, 110.80. Anal. Calcd. (C₁₅H₉BrO₂): C, 59.82; H, 3.02%. Found: C, 59.81; H, 3.05%.

4.1.1.4. (Z)-2-(4-Bromobenzylidene)benzofuran-3(2H)-one (1d). Purified by flash chromatography (Hexane/EtOAc = 95:5). Obtained as yellow solid, yield 56%, mp 180–182 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 7.91 (d, *J* = 8.3 Hz, 2H), 7.84–7.80 (m, 2H), 7.72 (d, *J* = 8.3 Hz, 2H), 7.56 (d, *J* = 8.5 Hz, 1H), 7.33 (t, *J* = 7.5 Hz, 1H), 6.95 (s, 1H). ¹³C NMR (101 MHz, DMSO-*d*₆): δ = 183.66, 165.47, 146.59, 137.88, 133.14, 132.10, 131.21, 124.42, 124.16, 123.65, 120.78, 113.28, 110.92. Anal. Calcd. (C₁₅H₉BrO₂): C, 59.82; H, 3.02%. Found: C, 59.88; H, 3.04%.

4.1.1.5. (Z)-2-(2,4-Difluorobenzylidene)benzofuran-3(2H)-one (1e). Purified by flash chromatography (Hexane/CH₂Cl₂ = 80:20). Obtained as yellow solid, 30% yield, mp 150–152 °C. ¹H NMR (400 MHz, CDCl₃) δ = 8.36 (td, *J* = 8.6, 6.5 Hz, 1H), 7.83 (dd, *J* = 7.7, 1.3 Hz, 1H), 7.73–7.63 (m, 1H), 7.33 (d, *J* = 8.3 Hz, 1H), 7.29–7.22 (m, 1H), 7.13 (s, 1H), 7.02 (dd, *J* = 11.9, 5.6 Hz, 1H), 6.95–6.85 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ = 184.55, 166.20, 147.39, 137.25, 133.16, 125.00, 123.91, 121.63, 113.05, 112.33, 104.40, 103.27. Anal. Calcd. (C₁₅H₈F₂O₂·0.25H₂O): C, 68.61; H, 3.27%. Found: C, 68.60; H, 3.27%.

4.1.1.6. (Z)-2-(2,4-Dichlorobenzylidene)benzofuran-3(2H)-one (1f). Purified by flash chromatography (Hexane/CH₂Cl₂ = 70:30). Obtained as a yellow solid, 81% yield, mp 213–214 °C. ¹H NMR (400 MHz, CDCl₃) δ = 8.31 (d, *J* = 8.6 Hz, 1H), 7.84–7.82 (m, 1H), 7.70–7.66 (m, 1H), 7.49 (d, *J* = 2.1 Hz, 1H), 7.37 (dd, *J* = 8.6, 2.1 Hz, 1H), 7.33 (d, *J* = 8.3 Hz, 1H), 7.28 (s, 1H), 7.26–7.24 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ = 184.57, 166.23, 147.82, 137.38, 136.61, 135.98, 132.98, 130.03, 129.15, 127.69, 125.07, 124.03, 121.51, 113.08, 106.94. Anal. Calcd. (C₁₅H₈Cl₂O₂·0.1Hex): C, 62.50; H, 3.17%. Found: C, 62.38; H, 3.32%.

4.1.1.7. (Z)-2-(3,4,5-Trimethoxybenzylidene)benzofuran-3(2H)-one (1g). Purified by flash chromatography (Hexane/CH₂Cl₂ = 70:30). Obtained as a yellow solid, 64% yield, mp 200–201 °C. ¹H NMR (400 MHz, CDCl₃) δ = 7.82 (d, *J* = 7.6 Hz, 1H), 7.70–7.63 (m, 1H), 7.31 (d, *J* = 8.3 Hz, 1H), 7.24 (dd, *J* = 12.5, 4.9 Hz, 1H), 7.19 (s, 2H), 6.83 (s, 1H), 3.95 (s, 6H), 3.92 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ = 184.70, 166.03, 153.44, 146.53, 140.14, 136.92, 127.82, 124.83, 123.68, 121.83, 113.52, 113.02, 109.01, 61.18, 56.33. Anal. Calcd. (C₁₈H₁₆O₅): C, 69.22; H, 5.17%. Found: C, 69.30; H, 5.36%.

4.1.1.8. (Z)-2-(4-(Dimethylamino)benzylidene)benzofuran-3(2H)-one (1h). Purified by flash chromatography (Hexane/CH₂Cl₂ = 50:50). Obtained as orange solid, 49% yield, mp 189–191 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.85 (d, 2H, *J* = 8.8 Hz), 7.81 (d, 1H, *J* = 7.5 Hz), 7.61 (t, 1H, *J* = 8.3 Hz), 7.32 (d, 1H, *J* = 8.3 Hz), 7.19 (t, 1H, *J* = 7.5 Hz), 6.93 (s, 1H), 6.75 (d, 2H, *J* = 8.8 Hz), 3.07 (s, 6H). ¹³C NMR (101 MHz, CDCl₃): δ = 184.14, 165.42, 151.47, 145.16, 135.96, 133.78, 124.46, 123.02, 122.59, 120.15, 115.45, 112.90, 112.08, 40.23. Anal. Calcd. (C₁₇H₁₅NO₂•0.15H₂O): C, 76.18; H, 5.77, N, 5.28%. Found: C, 76.20; H, 5.60, N, 5.33%.

4.1.1.9. (Z)-2-(4-(*p*-Tolyloxy)benzylidene)benzofuran-3(2H)-one (2j). Purified by flash chromatography (Hexane/EtOAc = 80:20). Obtained as yellow solid, 33% yield, mp 116–118 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 8.02 (d, 2H, *J* = 8.8 Hz), 7.82–7.79 (m, 2H), 7.55 (d, 1H, *J* = 8.6 Hz), 7.32 (t, 1H, *J* = 7.4 Hz), 7.25 (d, 2H, *J* = 8.4 Hz), 7.07 (d, 2H, *J* = 8.7 Hz), 7.02 (d, 2H, *J* = 8.4 Hz), 6.97 (s, 1H), 2.32 (s, 3H). ¹³C NMR (101 MHz, DMSO-*d*₆): δ = 183.39, 165.72, 159.49, 153.41, 146.06, 138.00, 134.10, 133.99, 131.07, 126.92, 124.72, 124.39, 121.47, 120.11, 118.32, 113.66, 112.51, 20.80. Anal. Calcd. (C₂₂H₁₆O₃•0.15H₂O): C, 79.81; H, 5.28%. Found: C, 79.59; H, 5.01%.

4.1.1.10. (Z)-2-(4-(4-Chlorophenoxy)benzylidene)benzofuran-3(2H)-one (2k). Purified by flash chromatography (Hexane/CH₂Cl₂ = 50:50). Obtained as yellow solid, 51% yield, mp 112–113 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 8.05 (d, 2H, *J* = 8.7 Hz), 7.83–7.80 (m, 2H), 7.55 (d, 1H, *J* = 8.6 Hz), 7.48 (d, 2H, *J* = 8.8 Hz), 7.33 (t, 1H, *J* = 7.4 Hz), 7.16–7.13 (m, 4H), 6.98 (s, 1H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ = 183.95, 165.80, 158.44, 155.01, 146.26, 138.08, 134.06, 130.55, 128.54, 127.76, 124.76, 124.44, 121.57, 121.44, 119.14, 113.68, 112.26. Anal. Calcd. (C₂₁H₁₃ClO₃•0.15H₂O): C, 71.76; H, 3.82%. Found: C, 71.37; H, 3.84%.

4.1.1.11. (Z)-2-Benzylidene-7-methoxybenzofuran-3(2H)-one (4a). Purified by flash chromatography (Hexane/EtOAc = 90:10). Obtained as yellow solid, 62% yield, mp 168–169 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.00 (d, 2H, *J* = 7.3 Hz), 7.56–7.47 (m, 4H), 7.35 (d, 1H, *J* = 7.8 Hz), 7.26 (t, 1H, *J* = 7.8 Hz), 6.99 (s, 1H), 4.01 (s, 3H). ¹³C NMR (101 MHz, DMSO-*d*₆): δ = 183.88, 154.91, 146.32, 145.62, 131.89, 131.44, 130.29, 129.17, 129.71, 122.16, 119.64, 115.17, 112.75, 56.35. Anal. Calcd. (C₁₆H₁₂O₃): C, 76.18; H, 4.80%. Found: C, 76.32; H, 5.03%.

4.1.1.12. (Z)-2-(2,4-Difluorobenzylidene)-7-methoxybenzofuran-3(2H)-one (4b). Purified by flash chromatography (Hexane/CH₂Cl₂ = 50:50). Obtained as yellow solid, 95% yield, mp 167–168 °C. ¹H NMR (400 MHz, CDCl₃) δ = 8.38 (td, *J* = 8.6, 6.6 Hz, 1H), 7.38 (dd, *J* = 6.7, 2.1 Hz, 1H), 7.20–7.14 (m, 2H), 7.13 (s, 1H), 7.07–6.99 (m, 1H), 6.92–6.84 (m, 1H), 4.02 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ = 184.66, 155.83, 147.35, 146.05, 133.38, 124.36, 122.96, 118.81, 116.04, 112.48, 104.31, 103.68, 56.44. Anal. Calcd. (C₁₆H₁₀F₂O₃): C, 66.66; H, 3.50%. Found: C, 66.65; H, 3.84%.

4.1.1.13. (Z)-2-(2,4-Dichlorobenzylidene)-7-methoxybenzofuran-3(2H)-one (4c). Purified through recrystallization from Hexane/

CH₂Cl₂. Obtained as yellow solid, 59% yield, mp 289–290 °C. ¹H NMR (400 MHz, CDCl₃) δ = 8.35 (d, *J* = 8.6 Hz, 1H), 7.48 (d, *J* = 2.0 Hz, 1H), 7.42–7.37 (m, 2H), 7.30 (s, 1H), 7.21–7.14 (m, 2H), 4.02 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ = 184.73, 155.86, 147.78, 146.04, 136.62, 136.03, 133.17, 129.96, 129.10, 127.88, 124.50, 122.87, 119.02, 116.13, 107.42, 56.47. Anal. Calcd. (C₁₆H₁₀Cl₂O₃•H₂O): C, 56.66; H, 3.57%. Found: C, 56.97; H, 3.45%.

4.1.1.14. (Z)-7-Methoxy-2-(3,4,5-trimethoxybenzylidene)benzofuran-3(2H)-one (4d). Purified by flash chromatography (Hexane/CH₂Cl₂ = 80:20). Obtained as yellow solid, 99% yield, mp 167–168 °C. ¹H NMR (400 MHz, CDCl₃) δ = 7.39 (dd, *J* = 6.8, 1.9 Hz, 1H), 7.24 (s, 2H), 7.18–7.12 (m, 2H), 6.85 (s, 1H), 4.01 (s, 3H), 3.95 (s, 6H), 3.92 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ = 184.81, 155.81, 153.41, 146.59, 146.09, 140.08, 127.83, 124.09, 123.22, 118.93, 116.06, 113.95, 109.04, 61.17, 56.69, 56.23. Anal. Calcd. (C₁₉H₁₈O₆•H₂O): C, 63.33; H, 5.59%. Found: C, 63.07; H, 5.89%.

4.1.2. General procedure for the synthesis of aurones 5a to 5d

To a solution of 6-hydroxybenzofuran-3(2H)-one (134 mg, 1 mmol) in H₂O (15 mL) at room temperature was added the appropriate aldehyde (1.1 mmol) and KOH 1 M (2 mmol). The mixture was stirred, at room temperature, for 4 h. After, some drops of HCl 37% were added to the mixture until the solution reach pH 2. The mixture was extracted with ethyl acetate and combined organic layers were washed with brine, dried with anhydrous Na₂SO₄ and concentrated under reduced pressure to give the crude product.

4.1.2.1. (Z)-2-Benzylidene-6-hydroxybenzofuran-3(2H)-one (5a). Purified through recrystallization from CH₂Cl₂. Obtained as yellow solid, 99% yield, mp 228–230 °C. ¹H NMR (400 MHz, DMSO) δ = 11.26 (s, 1H), 7.95 (d, 2H, *J* = 7.4 Hz), 7.64 (d, 1H, *J* = 8.4 Hz), 7.52–7.42 (m, 3H), 6.81–6.80 (m, 2H), 6.73 (d, 1H, *J* = 8.4 Hz). ¹³C NMR (101 MHz, DMSO) δ = 181.51, 168.02, 166.67, 147.41, 132.11, 131.10, 129.71, 129.03, 126.07, 113.15, 112.75, 110.38, 98.69. Anal. Calcd. (C₁₅H₁₀O₃•0.15H₂O): C, 74.77; H, 4.32%. Found: C, 74.50; H, 4.19%.

4.1.2.2. (Z)-2-(2,4-Difluorobenzylidene)-6-hydroxybenzofuran-3(2H)-one (5b). Purified through recrystallization from CH₂Cl₂. Obtained as yellow solid, 98% yield, mp 277–279 °C. ¹H NMR (400 MHz, DMSO) δ = 8.32–8.22 (m, 1H), 7.65 (d, *J* = 8.5 Hz, 1H), 7.48–7.38 (m, 1H), 7.32–7.25 (m, 1H), 6.80 (d, *J* = 1.9 Hz, 1H), 6.73 (dd, *J* = 8.5, 2.0 Hz, 1H), 6.71 (s, 1H). ¹³C NMR (101 MHz, DMSO) δ = 181.19, 168.19, 167.07, 148.20, 132.69, 126.36, 116.77, 116.69, 113.47, 112.78, 112.47, 104.66, 99.74, 98.85. Anal. Calcd. (C₁₅H₈F₂O₃•0.15Hex): C, 66.50; H, 3.55%. Found: C, 66.74; H, 3.86%.

4.1.2.3. (Z)-2-(2,4-dichlorobenzylidene)-6-hydroxybenzofuran-3(2H)-one (5c). Purified through recrystallization from CH₂Cl₂. Obtained as yellow solid, 99% yield, mp > 300 °C. ¹H NMR (400 MHz, DMSO) δ = 8.26 (d, *J* = 8.6 Hz, 1H), 7.80 (s, 1H), 7.66 (d, *J* = 8.4 Hz, 1H), 7.60 (d, *J* = 8.6 Hz, 1H), 6.88 (s, 1H), 6.79 (s, 1H), 6.74 (d, *J* = 8.5 Hz, 1H). ¹³C NMR (101 MHz, DMSO) δ = 181.17, 168.19, 167.14, 148.69, 134.98, 134.61, 132.68, 129.58, 128.75, 128.17, 126.42, 113.50, 112.29, 103.15, 98.84. Anal. Calcd. (C₁₅H₈Cl₂O₃•H₂O): C, 55.41; H, 3.10%. Found: C, 55.10; H, 3.23%.

4.1.2.4. (Z)-6-Hydroxy-2-(3,4,5-trimethoxybenzylidene)benzofuran-3(2H)-one (5d). Purified through recrystallization from CH₂Cl₂. Obtained as yellow solid, 98% yield, mp 264–266 °C. ¹H NMR (400 MHz, DMSO) δ = 7.62 (d, *J* = 8.4 Hz, 1H), 7.32 (s, 2H), 6.83 (s, 1H), 6.76 (s, 1H), 6.72 (d, *J* = 8.5 Hz, 1H), 3.85 (s, 6H), 3.72 (s, 3H). ¹³C NMR (101 MHz, DMSO) δ = 181.48, 167.93, 166.68, 153.10, 146.95,

139.18, 127.64, 126.07, 113.25, 112.88, 111.03, 108.84, 98.91, 60.33, 56.10. Anal. Calcd. (C₁₈H₁₆O₆): C, 65.84; H, 4.92%. Found: C, 65.62; H, 5.00%.

4.1.3. General procedure for the synthesis of aurones **5e–g**

To a solution of 6-hydroxybenzofuran-3(2H)-one (0.57 mmol) in glacial acetic acid (5.7 mL) at room temperature was added the appropriate aldehyde (0.68 mmol) and HCl (cat, 3 drops). The reaction mixture was stirred for 4 h at room temperature. After, the mixture was dropped in cold water and the precipitate formed was filtered and washed with water.

4.1.3.1. (Z)-2-(4-(Dimethylamino)benzylidene)-6-hydroxybenzofuran-3(2H)-one (5e). Obtained as orange solid, 71% yield, mp 235–237 °C. ¹H NMR (400 MHz, CDCl₃): δ = 10.00 (s, 1H), 7.73 (d, 2H, J = 8.9 Hz), 7.55 (d, 1H, J = 8.4 Hz), 6.70–6.61 (m, 5H), 2.99 (s, 6H). ¹³C NMR (101 MHz, CDCl₃): δ = 182.10, 167.38, 165.43, 150.17, 145.56, 132.77, 125.15, 119.69, 114.04, 112.79, 112.27, 111.59, 98.40. Anal. Calcd. (C₁₇H₁₅NO₃): C, 72.58; H, 5.39, N, 4.98%. Found: C, 72.19; H, 5.31, N, 5.09%.

4.1.3.2. (Z)-6-Hydroxy-2-(4-(p-tolyl)benzylidene)benzofuran-3(2H)-one (5f). Obtained as yellow solid, 51% yield, mp 248–250 °C. ¹H NMR (400 MHz, CDCl₃): δ = 11.22 (br, 1H), 7.96 (d, 2H, J = 8.8 Hz), 7.62 (d, 1H, J = 8.5 Hz), 7.24 (d, 1H, J = 8.1 Hz), 7.06–6.99 (m, 4H), 6.79–6.77 (m, 2H), 6.71 (dd, 1H, J = 8.5, 1.8 Hz). ¹³C NMR (101 MHz, CDCl₃): δ = 181.38, 167.82, 166.53, 158.67, 153.14, 146.71, 133.59, 133.17, 130.64, 126.73, 125.99, 119.64, 117.92, 113.11, 112.92, 110.14, 98.61, 20.38. Anal. Calcd. (C₂₂H₁₄O₄·0.2H₂O): C, 75.93; H, 5.05%. Found: C, 75.66; H, 5.03%.

4.1.3.3. (Z)-2-(4-(4-Chlorophenoxy)benzylidene)-6-hydroxybenzofuran-3(2H)-one (5g). Obtained as yellow solid, 84% yield, mp 243–244 °C. ¹H NMR (400 MHz, CDCl₃): δ = 10.21 (br, 1H), 7.80 (d, 2H, J = 8.8 Hz), 7.56 (d, 1H, J = 9.1 Hz), 7.27–7.25 (m, 2H), 6.97–6.93 (m, 4H), 6.67–6.63 (m, 3H). ¹³C NMR (101 MHz, CDCl₃): δ = 181.39, 167.86, 166.56, 157.59, 154.71, 146.88, 133.24, 130.11, 128.00, 127.56, 126.02, 121.06, 118.72, 113.12, 112.87, 109.91, 98.62. Anal. Calcd. (C₂₁H₁₃ClO₄·0.15H₂O): C, 68.63; H, 3.66%. Found: C, 68.57; H, 3.64%.

4.1.4. General procedure for the synthesis of aurones derivatives **2a–g**, **3a–g**, and **6a–c** via Suzuki coupling

To a solution of the appropriate aurone (0.23 mmol) in dioxane (2.3 mL) was added Pd(PPh₃)₂Cl₂ (0.023 mmol) and Na₂CO₃ 1 M (690 μL) followed by the proper boronic acid (0.28 mmol). The resulting mixture was degassed and stirred at 100 °C for 3 h under N₂. After cooling to room temperature, the reaction mixture was diluted with CH₂Cl₂, filtered under celite and concentrated under pressure to give the crude product.

4.1.4.1. (Z)-2-(biphenyl-4-ylmethylene)benzofuran-3(2H)-one (2a). Purified by flash chromatography (Hexane/EtOAc = 90:10). Obtained as yellow solid, 77% yield, mp 133–135 °C. ¹H NMR (400 MHz, DMSO-d₆): δ = 8.10 (d, J = 8.0 Hz, 2H), 7.85–7.75 (m, 6H), 7.61 (d, J = 8.4 Hz, 1H), 7.52–7.49 (m, 2H), 7.41 (m, 1H), 7.34 (t, J = 7.3 Hz, 1H), 7.03 (s, 1H). ¹³C NMR (101 MHz, DMSO-d₆): δ = 183.60, 165.45, 146.42, 141.50, 139.11, 137.73, 132.08, 131.08, 129.10, 128.15, 127.23, 126.82, 124.38, 124.07, 120.94, 113.30, 111.97. Anal. Calcd. (C₂₁H₁₄O₂·0.15H₂O): C, 83.78; H, 4.80%. Found: C, 83.67; H, 4.89%.

4.1.4.2. (Z)-2-((4-Fluorobiphenyl-4-yl)methylene)benzofuran-3(2H)-one (2b). Purified by flash chromatography (Hexane/EtOAc = 92:8). Obtained as yellow solid, 66% yield, mp 174–175 °C. ¹H NMR

(400 MHz, DMSO-d₆): δ = 8.10 (d, J = 8.3 Hz, 2H), 7.84–7.80 (m, 6H), 7.61 (d, J = 8.5 Hz, 1H), 7.36–7.31 (m, 3H), 7.03 (s, 1H). ¹³C NMR (101 MHz, DMSO-d₆): δ = 183.61, 165.45, 162.27, 146.43, 140.41, 137.75, 135.60, 132.08, 131.05, 128.90, 127.18, 124.39, 124.09, 120.94, 115.94, 113.31, 111.90. Anal. Calcd. (C₂₁H₁₃FO₂·0.1H₂O): C, 79.28; H, 4.19%. Found: C, 79.07; H, 4.33%.

4.1.4.3. (Z)-2-((4'-chlorobiphenyl-4-yl)methylene)benzofuran-3(2H)-one (2c). Purified by flash chromatography (Hexane/EtOAc = 90:10). Obtained as yellow solid, 64% yield, mp 171–173 °C. ¹H NMR (400 MHz, DMSO-d₆): δ = 8.10 (d, J = 8.3 Hz, 2H), 7.86–7.79 (m, 6H), 7.61 (d, J = 8.7 Hz, 1H), 7.56 (d, J = 8.5 Hz, 2H), 7.35 (t, J = 7.5 Hz, 1H), 7.03 (s, 1H). ¹³C NMR (101 MHz, DMSO-d₆): δ = 184.05, 165.91, 146.95, 140.52, 138.35, 138.20, 133.47, 132.53, 131.86, 129.49, 129.01, 127.63, 124.82, 124.54, 121.36, 113.74, 112.22. Anal. Calcd. (C₂₁H₁₃ClO₂·0.15H₂O): C, 75.18; H, 4.00%. Found: C, 75.16; H, 3.97%.

4.1.4.4. (Z)-4'-((3-Oxobenzofuran-2(3H)-ylidene)methyl)biphenyl-4-carbaldehyde (2d). Purified by flash chromatography (Hexane/EtOAc = 90:20). Obtained as yellow solid, 83% yield, mp 189–190 °C. ¹H NMR (400 MHz, DMSO-d₆): δ = 10.07 (s, 1H), 8.14 (d, J = 8.3 Hz, 2H), 8.04–7.99 (m, 4H), 7.94 (d, J = 8.3 Hz, 2H), 7.83–7.81 (m, 2H), 7.61 (d, J = 8.5 Hz, 1H), 7.35 (t, J = 7.4 Hz, 1H), 7.04 (s, 1H). ¹³C NMR (101 MHz, DMSO-d₆): δ = 192.81, 183.69, 165.52, 146.70, 144.76, 139.95, 137.85, 135.49, 132.22, 132.13, 130.26, 127.75, 127.53, 124.45, 124.17, 120.89, 113.34, 111.61. Anal. Calcd. (C₂₁H₁₄O₃·0.75H₂O): C, 77.74; H, 4.61%. Found: C, 77.43; H, 4.47%.

4.1.4.5. (Z)-2-(4-Benzylbenzylidene)benzofuran-3(2H)-one (2e). Purified by flash chromatography (Hexane/EtOAc = 92:8). Obtained as yellow solid, 70% yield, 154–156 °C. ¹H NMR (400 MHz, DMSO-d₆): δ = 7.93 (d, J = 7.9 Hz, 2H), 7.81–7.79 (m, 2H), 7.56 (d, J = 8.6 Hz, 1H), 7.39 (d, J = 7.9 Hz, 2H), 7.34–7.25 (m, 5H), 7.20 (t, J = 7.2 Hz, 1H), 6.93 (s, 1H), 4.01 (s, 2H). ¹³C NMR (101 MHz, DMSO-d₆): δ = 183.60, 165.43, 146.11, 143.86, 140.71, 137.69, 131.67, 129.75, 129.48, 128.77, 128.54, 126.16, 124.33, 124.01, 120.95, 113.26, 112.33, 41.01. Anal. Calcd. (C₂₂H₁₆O₂·0.15H₂O): C, 83.86; H, 5.23%. Found: C, 83.87; H, 5.12%.

4.1.4.6. (Z)-2-(4-(Quinolin-3-yl)benzylidene)benzofuran-3(2H)-one (2f). Purified by flash chromatography (Hexane/EtOAc = 70:30). Obtained as yellow solid, 87% yield, mp 205–207 °C. ¹H NMR (400 MHz, DMSO-d₆): δ = 9.35 (s, 1H), 8.77 (s, 1H), 8.19 (d, J = 8.4 Hz, 2H), 8.09–8.07 (m, 4H), 7.86–7.78 (m, 3H), 7.69–7.62 (m, 2H), 7.35 (t, J = 7.4 Hz, 1H), 7.07 (s, 1H). ¹³C NMR (101 MHz, DMSO-d₆): δ = 184.08, 165.93, 149.78, 147.47, 147.07, 138.80, 138.24, 133.68, 132.65, 132.24, 130.38, 129.15, 129.02, 128.12, 128.05, 127.65, 127.62, 124.86, 124.58, 121.35, 113.78, 112.15. Anal. Calcd. (C₂₄H₁₅NO₂·0.4H₂O): C, 80.87; H, 4.48; N, 3.93%. Found: C, 80.67; H, 4.27; N, 4.06%.

4.1.4.7. (Z)-2-(4-(6-aminopyridin-3-yl)benzylidene)benzofuran-3(2H)-one (2g). Purified by flash chromatography (EtOAc/MeOH = 97:3). Obtained as orange solid, 99% yield, mp 195–197 °C. ¹H NMR (400 MHz, DMSO-d₆): δ = 8.38 (s, 1H), 8.04 (d, J = 8.4 Hz, 2H), 7.84–7.80 (m, 3H), 7.76 (d, J = 8.4 Hz, 2H), 7.61 (d, J = 8.5 Hz, 1H), 7.34 (t, J = 7.4 Hz, 1H), 7.00 (s, 1H), 6.55 (d, J = 8.6 Hz, 1H), 6.24 (s, 2H). ¹³C NMR (101 MHz, DMSO-d₆): δ = 183.91, 165.75, 160.10, 146.75, 146.52, 140.16, 138.03, 135.74, 132.62, 130.16, 125.95, 124.75, 124.44, 123.02, 121.46, 113.72, 112.83, 108.48. Anal. Calcd. (C₂₀H₁₄N₂O₂·0.4H₂O): C, 74.70; H, 4.65; N, 8.71%. Found: C, 74.57; H, 4.43; N, 8.79%.

4.1.4.8. (Z)-2-(biphenyl-3-ylmethylene)benzofuran-3(2H)-one (3a). Purified by flash chromatography (Hexane/EtOAc = 92:8). Obtained as yellow solid, 71% yield, mp 123–125 °C. ^1H NMR (400 MHz, DMSO- d_6): δ = 8.24 (s, 1H), 8.08 (d, J = 7.8 Hz, 1H), 7.84–7.80 (m, 2H), 7.77–7.73 (m, 3H), 7.64–7.60 (m, 2H), 7.54–7.50 (m, 2H), 7.42 (t, J = 7.3 Hz, 1H), 7.34 (t, J = 7.4 Hz, 1H), 7.07 (s, 1H). ^{13}C NMR (101 MHz, DMSO- d_6): δ = 183.79, 165.59, 146.57, 140.96, 139.51, 137.84, 132.62, 130.06, 129.99, 129.76, 129.13, 128.47, 127.90, 126.87, 124.43, 124.13, 120.89, 113.41, 112.27. Anal. Calcd. ($\text{C}_{21}\text{H}_{14}\text{O}_2 \cdot 0.1\text{H}_2\text{O}$): C, 84.03; H, 4.78%. Found: C, 83.94; H, 4.80%.

4.1.4.9. (Z)-2-((4'-Fluorobiphenyl-3-yl)methylene)benzofuran-3(2H)-one (3b). Purified by flash chromatography (Hexane/EtOAc = 92:8). Obtained as yellow solid, 65% yield, mp 103–105 °C. ^1H NMR (400 MHz, DMSO- d_6): δ = 8.22 (s, 1H), 8.08 (d, J = 7.8 Hz, 1H), 7.81–7.78 (m, 5H), 7.64–7.60 (m, 2H), 7.37–7.32 (m, 3H), 7.06 (s, 1H). ^{13}C NMR (101 MHz, DMSO- d_6): δ = 183.78, 165.59, 162.15, 146.58, 139.89, 137.85, 135.95, 132.63, 129.96, 129.78, 128.93, 128.85, 128.38, 124.43, 124.14, 120.88, 116.03–115.82, 113.41, 112.18. Anal. Calcd. ($\text{C}_{21}\text{H}_{13}\text{FO}_2 \cdot 0.1\text{H}_2\text{O}$): C, 79.28; H, 4.19%. Found: C, 79.23; H, 4.15%.

4.1.4.10. (Z)-2-((4'-Chlorobiphenyl-3-yl)methylene)benzofuran-3(2H)-one (3c). Purified by flash chromatography (Hexane/EtOAc = 85:15). Obtained as yellow solid, 51% yield, mp 187–189 °C. ^1H NMR (400 MHz, DMSO- d_6): δ = 8.24 (s, 1H), 8.09 (d, J = 7.8 Hz, 1H), 7.85–7.76 (m, 5H), 7.65–7.56 (m, 4H), 7.34 (t, 1H, J = 7.5 Hz), 7.06 (s, 1H). ^{13}C NMR (101 MHz, DMSO- d_6): δ = 183.82, 165.62, 146.64, 139.63, 138.33, 137.91, 132.83, 132.73, 130.35, 129.94, 129.89, 129.11, 128.67, 128.38, 124.47, 124.19, 120.88, 113.44, 112.11. Anal. Calcd. ($\text{C}_{21}\text{H}_{13}\text{ClO}_2 \cdot 0.15\text{H}_2\text{O}$): C, 75.18; H, 4.00%. Found: C, 74.79; H, 4.20%.

4.1.4.11. (Z)-3'-((3-oxobenzofuran-2(3H)-ylidene)methyl)biphenyl-4-carbaldehyde (3d). Purified by flash chromatography (Hexane/EtOAc = 75:25). Obtained as yellow solid, 63% yield, mp 193–195 °C. ^1H NMR (400 MHz, DMSO- d_6): δ = 10.09 (s, 1H), 8.35 (s, 1H), 8.15 (d, J = 7.8 Hz, 1H), 8.06–7.98 (m, 4H), 7.88–7.82 (m, 3H), 7.68 (t, 1H, J = 7.8 Hz), 7.62 (d, 1H, J = 8.5 Hz), 7.35 (t, 1H, J = 7.4 Hz), 7.09 (s, 1H). ^{13}C NMR (101 MHz, DMSO- d_6): δ = 192.83, 183.76, 165.59, 146.66, 145.13, 139.54, 137.86, 135.38, 132.81, 130.97, 130.29, 128.73, 127.95, 127.55, 124.43, 124.15, 120.84, 113.42, 111.89. Anal. Calcd. ($\text{C}_{22}\text{H}_{14}\text{O}_3 \cdot 0.25\text{H}_2\text{O}$): C, 79.86; H, 4.43%. Found: C, 79.48; H, 4.57%.

4.1.4.12. (Z)-2-(3-Benzylbenzylidene)benzofuran-3(2H)-one (3e). Purified by flash chromatography (Hexane/EtOAc = 92:8). Obtained as yellow oil, 60%. ^1H NMR (400 MHz, DMSO- d_6): δ = 7.86–7.79 (m, 4H), 7.52 (t, 1H, J = 8.2 Hz), 7.44 (t, 1H, J = 7.6 Hz), 7.34–7.27 (m, 6H), 7.23–7.22 (m, 1H), 6.90 (s, 1H), 4.02 (s, 2H). ^{13}C NMR (101 MHz, DMSO- d_6): δ = 183.80, 165.54, 146.41, 142.41, 140.94, 137.90, 132.11, 131.77, 130.72, 129.32, 129.26, 128.93, 128.67, 126.26, 124.48, 124.17, 120.94, 113.33, 112.39, 41.00. HRMS calc. ($\text{C}_{22}\text{H}_{17}\text{O}_2$): 313.1223. Found: 313.1226.

4.1.4.13. (Z)-2-(3-(Quinolin-3-yl)benzylidene)benzofuran-3(2H)-one (3f). Purified by flash chromatography (Hexane/EtOAc = 80:20). Obtained as yellow solid, 68% yield, mp 195–196 °C. ^1H NMR (400 MHz, pyridine- d_6): δ = 9.53 (s, 1H), 8.53 (s, 1H), 8.42 (d, 1H, J = 8.4 Hz), 8.37 (s, 1H), 8.19 (d, 1H, J = 7.8 Hz), 8.05 (d, 1H, J = 8.1 Hz), 7.90 (d, 1H, J = 7.7 Hz), 7.85 (d, 1H, J = 7.4 Hz), 7.78 (t, 1H, J = 7.6 Hz), 7.67–7.61 (m, 3H), 7.40 (d, 1H, J = 8.1 Hz), 7.26–7.18 (m, 2H). ^{13}C NMR (101 MHz, DMSO- d_6): δ = 184.80, 166.74, 148.56, 147.97, 139.23, 137.84, 134.13, 133.94, 133.66, 131.43, 131.21, 130.56, 130.29, 130.13, 129.46, 129.11, 128.83, 127.83, 125.05, 124.45, 124.17,

122.24, 113.85, 112.55. Anal. Calcd. ($\text{C}_{24}\text{H}_{15}\text{NO}_2 \cdot 0.3\text{H}_2\text{O}$): C, 81.24; H, 4.44; N, 3.95%. Found: C, 81.59; H, 4.83; N, 3.92%.

4.1.4.14. (Z)-2-(3-(6-Aminopyridin-3-yl)benzylidene)benzofuran-3(2H)-one (3g). Purified by flash chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ = 97:3). Obtained as yellow solid, 76% yield, mp 187–189 °C. ^1H NMR (400 MHz, DMSO- d_6): δ = 8.32 (s, 1H), 8.14 (s, 1H), 7.98 (d, J = 7.7 Hz, 1H), 7.83–7.80 (m, 2H), 7.77 (dd, J = 8.6, 2.5 Hz, 1H), 7.67 (d, J = 7.9 Hz, 1H), 7.63–7.61 (m, 1H), 7.55 (t, J = 7.7 Hz, 1H), 7.34 (t, J = 7.4 Hz, 1H), 7.03 (s, 1H), 6.56 (d, J = 8.6 Hz, 1H), 6.15 (s, 2H). ^{13}C NMR (101 MHz, DMSO- d_6): δ = 184.17, 165.97, 159.89, 145.87, 146.35, 138.19, 135.87, 132.93, 131.99, 130.09, 129.28, 127.50, 124.80, 123.52, 121.31, 113.82, 112.89, 108.49. Anal. Calcd. ($\text{C}_{20}\text{H}_{14}\text{N}_2\text{O}_2 \cdot 0.5\text{H}_2\text{O}$): C, 74.28; H, 4.69; N, 8.67%. Found: C, 74.43; H, 4.55; N, 8.97%.

4.1.4.15. (Z)-2-Benzylidene-6-phenylbenzofuran-3(2H)-one (6a). Purified by flash chromatography (Hexane/ CH_2Cl_2 = 70:30). Obtained as yellow solid, 78% yield, mp 141–143 °C. ^1H NMR (400 MHz, CDCl_3): δ = 7.95 (d, 2H, J = 7.3 Hz), 7.87 (d, 1H, J = 8.0 Hz), 7.57 (d, 2H, J = 7.1 Hz), 7.56 (s, 1H), 7.53–7.40 (m, 7H), 6.92 (s, 1H). ^{13}C NMR (101 MHz, DMSO- d_6): δ = 183.14, 166.24, 149.52, 146.92, 138.58, 131.99, 131.44, 130.16, 129.23, 129.20, 129.10, 127.44, 124.79, 122.86, 124.48, 119.81, 112.18, 111.06. Anal. Calcd. ($\text{C}_{21}\text{H}_{14}\text{O}_2 \cdot 0.6\text{H}_2\text{O}$): C, 81.58; H, 4.97%. Found: C, 81.41; H, 5.28%.

4.1.4.16. (Z)-2-Benzylidene-6-(4-fluorophenyl)benzofuran-3(2H)-one (6b). Purified by flash chromatography (Hexane/EtOAc = 90:10). Obtained as yellow solid, 66% yield, mp 172–174 °C. ^1H NMR (400 MHz, DMSO- d_6): δ = 8.04 (d, 2H, J = 7.2 Hz), 7.94–7.90 (m, 3H), 7.87 (d, 1H, J = 8.1 Hz), 7.64 (dd, 1H, J = 8.1, 1.3 Hz), 7.55–7.48 (m, 3H), 7.38 (t, 2H, J = 8.8 Hz), 6.98 (s, 1H). ^{13}C NMR (101 MHz, DMSO- d_6): δ = 183.10, 166.22, 164.08–161.63, 148.35, 146.91, 135.03, 131.98, 131.43, 130.17, 129.73–129.64, 129.10, 124.81, 122.78, 119.76, 116.21–115.99, 112.21, 111.04. Anal. Calcd. ($\text{C}_{21}\text{H}_{13}\text{FO}_2 \cdot 0.3\text{H}_2\text{O}$): C, 78.39; H, 4.27%. Found: C, 78.14; H, 4.22%.

4.1.4.17. (Z)-6-(6-Aminopyridin-3-yl)-2-benzylidenebenzofuran-3(2H)-one (6c). Purified by flash chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ = 98:2). Obtained as orange solid, 98% yield, mp 191–192 °C. ^1H NMR (400 MHz, DMSO- d_6): δ = 8.50 (s, 1H), 8.02 (d, 2H, J = 7.3 Hz), 7.92 (dd, 1H, J = 8.7, 2.5 Hz), 7.82–7.78 (m, 1H), 7.58 (d, 1H, J = 8.1 Hz), 7.53 (t, 2H, J = 7.3 Hz), 7.48–7.45 (m, 1H), 6.92 (s, 1H), 6.56 (d, 1H, J = 8.7 Hz), 6.44 (s, 2H). ^{13}C NMR (101 MHz, DMSO- d_6): δ = 182.75, 166.53, 160.35, 147.83, 147.36, 147.12, 135.82, 132.09, 131.32, 130.01, 129.08, 124.76, 121.94, 121.00, 118.51, 111.52, 108.53, 108.02. Anal. Calcd. ($\text{C}_{20}\text{H}_{14}\text{N}_2\text{O}_2 \cdot 0.3\text{H}_2\text{O}$): C, 75.12; H, 4.61; N, 8.76%. Found: C, 74.91; H, 4.55; N, 8.64%.

4.1.5. General procedure for the synthesis of aurones derivatives **2h–i** via Buchwald coupling

(Z)-2-(4-bromobenzylidene)benzofuran-3(2H)-one (**1d**) (0.23 mmol), $\text{Pd}_2(\text{dba})_3$ (0.0115 mmol), (*R*)-BINAP (0.075 mmol) and NaOtBu (0.322 mmol) were dissolved in dry toluene (2.3 mL). The resulting mixture was degassed and the appropriate amine (0.276 mmol) was added. The mixture was stirred at 100 °C for 15 min under MW conditions. After cooling to room temperature, the reaction mixture was diluted with Et_2O , filtered under celite and concentrated under pressure to give the crude product.

4.1.5.1. (Z)-2-(4-(Phenylamino)benzylidene)benzofuran-3(2H)-one (2h). Purified by flash chromatography (Hexane/EtOAc = 80:20). Obtained as orange solid, 71% yield, mp 191–192 °C. ^1H NMR (400 MHz, DMSO- d_6): δ = 8.87 (s, 1H), 7.90 (d, 2H, J = 8.7 Hz), 7.79–7.76 (m, 2H), 7.55 (d, 1H), 7.34–7.29 (m, 3H), 7.20 (d, 2H, J = 7.6 Hz),

7.15 (d, 2H, $J = 8.7$ Hz), 6.98 (t, 1H, $J = 7.3$ Hz), 6.91 (s, 1H). ^{13}C NMR (100 MHz, DMSO- d_6): $\delta = 183.21, 165.18, 146.57, 144.95, 141.80, 137.36, 134.02, 129.80, 124.46, 124.08, 122.61, 122.13, 121.92, 119.41, 115.66, 114.30, 113.58$. Anal. Calcd. ($\text{C}_{21}\text{H}_{15}\text{NO}_2 \cdot 0.15\text{H}_2\text{O}$): C, 79.80; H, 4.89; N, 4.43%. Found: C, 79.56; H, 5.12; N, 4.68%.

4.1.5.2. (Z)-2-(4-(Benzylamino)benzylidene)benzofuran-3(2H)-one (2i). Purified by flash chromatography (Hexane/EtOAc = 80:20) followed by TLC (Hexane/EtOAc = 70:30). Obtained as orange oil, 49% yield. ^1H NMR (400 MHz, CDCl_3): $\delta = 7.82\text{--}7.80$ (m, 3H), 7.62 (t, 1H, $J = 7.6$ Hz), 7.39–7.28 (m, 6H), 7.20 (m, 1H, $J = 7.6$ Hz), 6.91 (s, 1H), 6.70 (d, 2H, $J = 8.5$ Hz), 4.66 (br, H), 4.43 (s, 2H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 184.22, 165.41, 149.82, 145.12, 138.47, 136.08, 133.93, 128.86, 127.59, 127.44, 124.40, 123.03, 122.37, 121.48, 115.21, 112.90, 112.86, 47.71$. HRMS calc. ($\text{C}_{22}\text{H}_{17}\text{NO}_2$): 328.1332. Found: 328.1334.

4.1.6. Synthesis of (Z)-2-benzylidene-3-oxo-2,3-dihydrobenzofuran-6-yl trifluoromethanesulfonate (15)

Compound **5a** (0.25 mmol) was dissolved in dry CH_2Cl_2 (1 mL) and dry TEA (0.275 mmol) was added to the solution followed by Tf_2O (0.275 mmol). The mixture was stirred for 45 min at room temperature under N_2 . After completion, water was added to the reaction mixture and the product was extracted with CH_2Cl_2 . The organic layer was washed with water, dried with anhydrous Na_2SO_4 and concentrated under reduced pressure permitting to obtain the pure product. Obtained as yellow solid, 98% yield. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 8.04\text{--}7.97$ (m, 4H), 7.53–7.44 (m, 4H), 7.05 (s, 1H). ^{13}C NMR (101 MHz, DMSO- d_6): $\delta = 182.17, 165.67, 154.11, 146.55, 131.69, 131.59, 130.56, 129.13, 126.56, 121.37, 118.23, 117.57, 113.51, 107.89$.

4.1.7. General procedure for the synthesis of Mannich bases 7a–d

To a solution of (Z)-2-benzylidene-6-hydroxybenzofuran-3(2H)-one (0.29 mmol) in absolute ethanol (1 mL) was added the appropriate amine (0.32 mmol) followed by formaldehyde solution (0.32 mmol). The mixture was refluxed for 3 h30. After, the solvent was removed and the solid residue was dissolved in CH_2Cl_2 and extracted with HCl 1 M. The aqueous layer was neutralized with NaHCO_3 saturated solution and extracted with CH_2Cl_2 . The organic layer was dried with anhydrous Na_2SO_4 and concentrated under reduced pressure to give the crude product.

4.1.7.1. 2-Benzylidene-6-hydroxy-7-((4-methylpiperazin-1-yl)methyl)benzofuran-3(2H)-one (7a). Purified by flash chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH} = 98:2$). Obtained as yellow solid, 61% yield, mp 178–179 °C. Mixture of isomers Z/E = 1:0.15. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 7.97$ (d, 2H, $J = 7.4$ Hz), 7.54–7.49 (m, 3H), 7.45–7.41 (m, 1H), 6.77 (s, 1H), 6.65 (d, 1H), 3.90 (s, 2H), 2.50 (br, 8H), 2.18 (s, 3H). ^{13}C NMR (101 MHz, DMSO- d_6): $\delta = 181.24, 167.75, 166.19, 147.67, 132.32, 131.07, 129.57, 129.05, 124.62, 113.64, 111.48, 109.91, 105.77, 54.30, 52.00, 50.83, 45.47$. Anal. Calcd. ($\text{C}_{21}\text{H}_{22}\text{N}_2\text{O}_3 \cdot 0.3\text{H}_2\text{O}$): C, 70.88; H, 6.42; N, 7.87%. Found: C, 70.75; H, 6.48; N, 7.66%.

4.1.7.2. 2-Benzylidene-6-hydroxy-7-(piperidin-1-ylmethyl)benzofuran-3(2H)-one (7b). Purified by flash chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH} = 98:2$). Obtained as yellow solid, 63% yield, mp 198–200 °C. Mixture of isomers Z/E = 1:0.4. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 7.94$ (d, 2H, $J = 7.4$ Hz), 7.51–7.41 (m, 4H), 6.70 (s, 1H), 6.50–6.45 (m, 1H), 4.06 (s, 2H), 2.82–2.76 (m, 4H), 1.63–1.48 (m, 6H). ^{13}C NMR (101 MHz, DMSO- d_6): $\delta = 180.26, 171.55, 166.39, 148.16, 132.50, 130.91, 129.05, 128.28, 124.90, 115.03, 109.47, 109.07, 103.14, 52.69, 51.91, 24.49, 22.69$. HRMS calc. ($\text{C}_{21}\text{H}_{22}\text{NO}_3$): 336.1594. Found: 336.1594.

4.1.7.3. 2-Benzylidene-6-hydroxy-7-(morpholinomethyl)benzofuran-3(2H)-one (7c). Purified by flash chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH} = 99:1$). Obtained as yellow solid, 54% yield, 179–181 °C. Mixture of isomers Z/E = 1:0.1. ^1H NMR (400 MHz, acetone- d_6): $\delta = 7.99$ (d, 2H, $J = 7.3$ Hz), 7.58–7.44 (m, 4H), 6.74 (s, 1H), 6.67 (d, 1H, $J = 8.4$ Hz), 4.11 (s, 2H), 3.96–3.75 (m, 8H). ^{13}C NMR (101 MHz, acetone- d_6): $\delta = 167.85, 133.51, 132.06, 129.83, 125.38, 114.11, 111.03, 67.21, 53.71$. Anal. Calcd. ($\text{C}_{20}\text{H}_{19}\text{NO}_4 \cdot 0.25\text{H}_2\text{O}$): C, 70.26; H, 5.76; N, 4.10%. Found: C, 70.17; H, 5.72; N, 4.24%.

4.1.7.4. (Z)-2-Benzylidene-7-((diethylamino)methyl)-6-hydroxybenzofuran-3(2H)-one (7d). Purified by flash chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH} = 97:3$) followed by TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH} = 95:5$). Obtained as yellow solid, 29% yield, mp 165–167 °C. ^1H NMR (400 MHz, CDCl_3): $\delta = 7.83$ (d, 2H, $J = 7.3$ Hz), 7.60 (d, 1H, $J = 8.5$ Hz), 7.46 (t, 2H, $J = 7.5$ Hz), 7.40–7.38 (m, 1H), 6.78 (s, 1H), 6.62 (d, 1H, $J = 8.5$ Hz), 4.06 (s, 2H), 2.78 (q, 4H, $J = 7.2$ Hz), 1.21 (t, 6H, $J = 7.2$ Hz). ^{13}C NMR (101 MHz, CDCl_3): $\delta = 168.93, 148.28, 132.88, 131.23, 129.48, 129.01, 125.22, 114.05, 112.94, 111.17, 104.51, 49.54, 47.10, 11.34$.

5. Biological assays

5.1. Activity against *P. falciparum* W2 strain

Compounds were assayed against human red blood cells infected with 1% ring stage W2-strain *P. falciparum* synchronized with 5% sorbitol. These cells were incubated with tested compounds in 96-well plates at 37 °C for 48 h in RPMI-1640 medium supplemented with 25 mM HEPES pH 7.4, 10% heat inactivated human serum (or 0.5% Albumax/2% human serum), and 100 μM hypoxanthine under an atmosphere of 3% O_2 , 5% CO_2 , 91% N_2 . After 48 h, the cells were fixed in 2% formaldehyde in PBS, transferred into PBS with 100 mM NH_4Cl , 0.1% Triton X-100, 1 nM YOYO-1, and then analyzed in a flow cytometer (FACSort, Beckton Dickinson; EX 488 nm, EM 520 nm). Values of IC_{50} were calculated using GraphPad PRISM software.

5.2. Hemozoin-like crystals growth inhibition

Inhibition of hemozoin-like crystals formation by tested compounds was assessed using the previously described *in vitro* method [39,40]. In short, a hemozoin-like crystals stock suspension was sonicated for 3 min and diluted in fresh broth medium to the final concentration of 2 μM (heme equivalents) in the wells of a 96-wells plate. Stock solutions of tested compounds were prepared at 25 mM in DMSO. Stock solutions of chloroquine (positive control) and gentamicin (negative control) were prepared at 100 mM in distilled water; and all were 0.22 μm -filtered previous to being diluted to 0–1000 μM final concentrations in the wells. Plates were incubated at 37 °C in a 5% CO_2 atmosphere for 5 days to observe the presence or absence of crystal growth. All tests were performed in triplicate.

5.3. In vitro drug combination assay

5.3.1. Parasite cultivation

Laboratory-adapted *P. falciparum* Dd2 (chloroquine-resistant) strain was continuously cultured as previously described by Trager and Jensen [52], with minor modifications. Briefly, parasites were cultivated on human erythrocytes suspended in RPMI 1640 medium supplemented with 25 mM HEPES, 6.8 mM hypoxanthine and 10% AlbuMAX II, at pH 7.2. Cultures were maintained at 37 °C under an atmosphere of 5% O_2 , 3–5% CO_2 , and N_2 and synchronized by double sorbitol treatment prior to the assays [53]. Staging and

parasitaemia were determined by light microscopy of Giemsa-stained thin blood smears.

5.3.2. *In vitro* antimalarial activity

The antimalarial activity of compound **7c** and chloroquine were determined using the SYBR Green I assay as previously described. Stock solutions of the drugs (10 mM) were prepared in DMSO and serially diluted in complete media. Parasitized erythrocytes at the early ring stage were added to a final 1% parasitaemia and 3% hematocrit to each triplicate well of a 96-well plate, and incubated for 48 h at 37 °C prior to growth assessment with SYBR Green I nucleic acid. Each compound was analyzed at a final concentration range of 0–50 μ M (0.2% DMSO), whereas chloroquine was assayed at a concentration range of 0–10 μ M. SYBR Green I fluorescence was quantified using a multi-mode microplate reader (Dynex Triad) and analyzed by nonlinear regression using GraphPad Prism 5 demo version.

5.3.3. Combination assay

Analysis of the combination effects of compound **7c** with chloroquine was determined by a modified fixed ratio isobologram method [47–50]. Initially, the 50% inhibitory concentration (IC_{50}) values of the individual test compounds were determined. Subsequently, dose–response experiments at 2-fold dilutions were run for different drug combinations (IC_{50} ratios equals 5:0, 4:1, 3:2, 2:3, 1:4 or 0:5) and their IC_{50} s in the combination determined, as described above. The fractional inhibitory concentration (FIC; $FIC_{50} = IC_{50}$ of drug in the combination/ IC_{50} of drug when tested alone) of each drug was calculated and plotted as an isobologram.

5.3.4. *In vitro* cytotoxicity

The cytotoxicity was assessed using general cell viability endpoint MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) [54,55]. Briefly, the day before experiment cells NIH 3T3 (mouse embryonic fibroblast cell line, ATCC CRL-1658) or HEK 293T (human embryonic kidney epithelial cell line, ATCC CRL-11268) are seeded in 96 well tissue culture plates, in RPMI 1640 culture medium supplemented with 10% Fetal serum bovine, 100 units of penicillin G (sodium salt) and 100 μ g of streptomycin sulfate and 2 mM L-glutamine, at a concentration that allow cells to grow exponentially during the time of the assay. Compounds to be tested are diluted in dimethylsulfoxide (DMSO) and then serially diluted in the culture medium. Compounds at different concentrations (until reaching 100 μ M) and DMSO are then added to the cells. Cells are incubated at 37 °C in humidified 5% CO₂ atmosphere. After 48 h, cell media containing DMSO (for control cells) or tested compound solution (for test cells) was removed and replaced with fresh medium containing MTT dye. After 3 h of incubation the complete media was removed and the intracellular formazan crystals were solubilized and extracted with DMSO. After 15 min at room temperature the absorbance measured at 570 nm in microplate reader.

The percentage of cell viability was determined for each concentration of tested compound as described previously [54,55]. The concentration of a compound reflecting a 50% inhibition of cell viability (i.e. IC_{50}) was determined from the concentration–response curve. This was done by applying non-linear regression procedure to the concentration response data using GraphPad PRISM software.

Acknowledgments

This work was supported by Fundação para a Ciência e Tecnologia (FCT, Portugal) through projects PTDC/SAU-FAR/118459/2010 and Pest-OE/SAL/UI4013/2011. A.S.N. and M.P.C. acknowledge FCT

for grants SFRH/BD/41276/2007 and SFRH/BD/61611/2009, respectively. P.J.R. is a Doris Duke Charitable Foundation Distinguished Clinical Scientist.

Appendix A. Supplementary data

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.ejmech.2014.04.076>.

References

- [1] A. Martinelli, R. Moreira, P.V.L. Cravo, Malaria combination therapies: advantages and shortcomings, *Mini Reviews in Medicinal Chemistry* 8 (2008) 201–212.
- [2] R. Arav-Boger, T.A. Shapiro, Molecular mechanisms of resistance in antimalarial chemotherapy: the unmet challenge, *Annual Review of Pharmacology* 45 (2005) 565–585.
- [3] D.A. Fidock, R.T. Eastman, S.A. Ward, S.R. Meshnick, Recent highlights in antimalarial drug resistance and chemotherapy research, *Trends in Parasitology* 24 (2008) 537–544.
- [4] K. Kaur, M. Jain, T. Kaur, R. Jain, Antimalarials from nature, *Bioorganic & Medicinal Chemistry* 17 (2009) 3229–3256.
- [5] O. Kayser, A.F. Kiderlen, S.L. Croft, Natural products as antiparasitic drugs, *Parasitology Research* 90 (2003) S55–S62.
- [6] R. Haudecoeur, A. Boumendjel, Recent advances in the medicinal chemistry of aurones, *Current Medicinal Chemistry* 19 (2012) 2861–2875.
- [7] A. Boumendjel, Aurones: a subclass of flavones with promising biological potential, *Current Medicinal Chemistry* 10 (2003) 2621–2630.
- [8] C.Y. Lee, E.H. Chew, M.L. Go, Functionalized aurones as inducers of NAD(P)H: quinone oxidoreductase 1 that activate AhR/XRE and Nrf2/ARE signaling pathways: synthesis, evaluation and SAR, *European Journal of Medicinal Chemistry* 45 (2010) 2957–2971.
- [9] B. Gerby, A. Boumendjel, M. Blanc, P.P. Bringuier, P. Champelovier, A. Fortune, X. Ronot, J. Boutonnat, 2-Arylidenedihydroindole-3-ones: design, synthesis, and biological activity on bladder carcinoma cell lines, *Bioorganic & Medicinal Chemistry Letters* 17 (2007) 208–213.
- [10] W. Huang, M.Z. Liu, Y. Li, Y. Tan, G.F. Yang, Design, synthesis, and antitumor activity of novel chromone and aurone derivatives, *Bioorganic & Medicinal Chemistry* 15 (2007) 5191–5197.
- [11] C. Dubois, R. Haudecoeur, M. Orio, C. Belle, C. Bochot, A. Boumendjel, R. Hardre, H. Jamet, M. Reglier, Versatile effects of aurone structure on mushroom tyrosinase activity, *Chembiochem: a European Journal of Chemical Biology* 13 (2012) 559–565.
- [12] K. Manjulatha, S. Srinivas, N. Mulakayala, D. Rambabu, M. Prabhakar, K.M. Arunasree, M. Alvala, M.V.B. Rao, M. Pal, Ethylenediamine diacetate (EDDA) mediated synthesis of aurones under ultrasound: their evaluation as inhibitors of SIRT1, *Bioorganic & Medicinal Chemistry Letters* 22 (2012) 6160–6165.
- [13] S. Okombi, D. Rival, S. Bonnet, A.M. Mariotte, E. Perrier, A. Boumendjel, Discovery of benzylidenebenzofuran-3(2H)-one (aurones) as inhibitors of tyrosinase derived from human melanocytes, *Journal of Medicinal Chemistry* 49 (2006) 329–333.
- [14] B.R. Bandgar, S.A. Patil, B.L. Korbar, S.C. Biradar, S.N. Nile, C.N. Khobragade, Synthesis and biological evaluation of a novel series of 2,2-bisaminomethylated aurone analogues as anti-inflammatory and antimicrobial agents, *European Journal of Medicinal Chemistry* 45 (2010) 3223–3227.
- [15] O. Kayser, A.F. Kiderlen, U. Folkens, H. Kokodziej, *In vitro* leishmanicidal activity of aurones, *Planta Medica* 65 (1999) 316–319.
- [16] O. Kayser, A.F. Kiderlen, R. Brun, *In vitro* activity of aurones against *Plasmodium falciparum* strains K1 and NF54, *Planta Medica* 67 (2001) 718–721.
- [17] O. Kayser, M. Chen, A. Kharazmi, A.F. Kiderlen, Aurones interfere with *Leishmania major* mitochondrial fumarate reductase, *Zeitschrift für Naturforschung* 57c (2002) 717–720.
- [18] F. Souard, S. Okombi, C. Beney, S. Chevalley, A. Valentin, A. Boumendjel, 1-Azaaurones derived from the naturally occurring aurones as potential antimalarial drugs, *Bioorganic & Medicinal Chemistry* 18 (2010) 5724–5731.
- [19] R. Haudecoeur, A. Ahmed-Belkacem, W. Yi, A. Fortune, R. Brillet, C. Belle, E. Nicolle, C. Pallier, J.M. Pawlowsky, A. Boumendjel, Discovery of naturally occurring aurones that are potent allosteric inhibitors of Hepatitis C virus RNA-dependent RNA polymerase, *Journal of Medicinal Chemistry* 54 (2011) 5395–5402.
- [20] S.Y. Shin, M.C. Shin, J.S. Shin, K.T. Lee, Y.S. Lee, Synthesis of aurones and their inhibitory effects on nitric oxide and PGE(2) productions in LPS-induced RAW 264.7 cells, *Bioorganic & Medicinal Chemistry Letters* 21 (2011) 4520–4523.
- [21] H.M. Sim, C.Y. Lee, P.L.R. Ee, M.L. Go, Dimethoxyaurones: potent inhibitors of ABCG2 (breast cancer resistance protein), *European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences* 35 (2008) 293–306.
- [22] H.M. Sim, K.Y. Loh, W.K. Yeo, C.Y. Lee, M.L. Go, Aurones as modulators of ABCG2 and ABCB1: synthesis and structure-activity relationships, *Chemical Medicinal Chemistry* 6 (2011) 713–724.

- [23] H.M. Sim, C.P. Wu, S.V. Ambudkar, M.L. Go, *In vitro* and *in vivo* modulation of ABCG2 by functionalized aurones and structurally related analogs, *Biochemical Pharmacology* 82 (2011) 1562–1571.
- [24] M. Hadjeri, M. Barbier, X. Ronot, A.M. Mariotte, A. Boumendjel, J. Boutonnat, Modulation of P-glycoprotein-mediated multidrug resistance by flavonoid derivatives and analogues, *Journal of Medicinal Chemistry* 46 (2003) 2125–2131.
- [25] A. Boumendjel, C. Beney, N. Deka, A.M. Mariotte, M.A. Lawson, D. Trompier, H. Baubichon-Cortay, A. Di Pietro, 4-hydroxy-6-methoxyaurones with high-affinity binding to cytosolic domain of P-glycoprotein, *Chemical & Pharmaceutical Bulletin* 50 (2002) 854–856.
- [26] R. Sheng, Y. Xu, C.Q. Hu, J. Zhang, X. Lin, J.Y. Li, B. Yang, Q.J. He, Y.Z. Hu, Design, synthesis and AChE inhibitory activity of indanone and aurone derivatives, *European Journal of Medicinal Chemistry* 44 (2009) 7–17.
- [27] W.J. Geldenhuys, M.O. Funk, C.J. Van der Schyf, R.T. Carroll, A scaffold hopping approach to identify novel monoamine oxidase B inhibitors, *Bioorganic & Medicinal Chemistry Letters* 22 (2012) 1380–1383.
- [28] R.J. Fitzmaurice, Z.C. Etheridge, E. Jumel, D.N. Woolfson, S. Caddick, Microwave enhanced palladium catalysed coupling reactions: a diversity-oriented synthesis approach to functionalised flavones, *Chemical Communications* (2006) 4814–4816.
- [29] W.A. Guiguemde, A.A. Shelat, D. Bouck, S. Duffy, G.J. Crowther, P.H. Davis, D.C. Smithson, M. Connelly, J. Clark, F.Y. Zhu, M.B. Jimenez-Diaz, M.S. Martinez, E.B. Wilson, A.K. Tripathi, J. Gut, E.R. Sharlow, I. Bathurst, F. El Mazouni, J.W. Fowble, I. Forquer, P.L. McGinley, S. Castro, I. Angulo-Barturen, S. Ferrer, P.J. Rosenthal, J.L. DeRisi, D.J. Sullivan, J.S. Lazo, D.S. Roos, M.K. Riscoe, M.A. Phillips, P.K. Rathod, W.C. Van Voorhis, V.M. Avery, R.K. Guy, Chemical genetics of *Plasmodium falciparum*, *Nature* 465 (2010) 311–315.
- [30] R.S. Varma, M. Varma, Alumina-mediated condensation - a simple synthesis of aurones, *Tetrahedron Letters* 33 (1992) 5937–5940.
- [31] Q.S. Liu, J.W. Chang, J.H. Wang, S.A. Kang, C.C. Thoreen, A. Markhard, W. Hur, J.M. Zhang, T. Sim, D.M. Sabatini, N.S. Gray, Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer, *Journal of Medicinal Chemistry* 53 (2010) 7146–7155.
- [32] K. Thakkar, M. Cushman, A novel oxidative cyclization of 2'-hydroxychalcones to 4,5-dialkoxyaurone by thallium(III) nitrate, *The Journal of Organic Chemistry* 60 (1995) 6499–6510.
- [33] C. Beney, A.M. Mariotte, A. Boumendjel, An efficient synthesis of 4,6 dime-thoxyaurones, *Heterocycles* 55 (2001) 967–972.
- [34] Atta-Ur-Rahman, M.I. Choudhary, S. Hayat, A.M. Khan, A. Ahmed, Two new aurones from marine brown alga *Spatoglossum variabile*, *Chemical & Pharmaceutical Bulletin* 49 (2001) 105–107.
- [35] P.M. O'Neill, S.A. Ward, N.G. Berry, J.P. Jeyadevan, G.A. Biagini, E. Asadollaly, B.K. Park, P.G. Bray, A medicinal chemistry perspective on 4-aminoquinoline antimalarial drugs, *Current Topics in Medicinal Chemistry* 6 (2006) 479–507.
- [36] M. Liu, P. Wilairat, M.L. Go, Antimalarial alkoxylated and hydroxylated chalcones: structure-activity relationship analysis, *Journal of Medicinal Chemistry* 44 (2001) 4443–4452.
- [37] D.C. Warhurst, J.C. Craig, P.S. Adagu, R.K. Guy, P.B. Madrid, Q.L. Fivelman, Activity of piperazine and other 4-aminoquinoline antiplasmodial drugs against chloroquine-sensitive and resistant blood-stages of *Plasmodium falciparum* - role of beta-haematin inhibition and drug concentration in vacuolar water- and lipid-phases, *Biochemical Pharmacology* 73 (2007) 1910–1926.
- [38] R.D. Sandlin, M.D. Carter, P.J. Lee, J.M. Auschwitz, S.E. Leed, J.D. Johnson, D.W. Wright, Use of the NP-40 detergent-mediated assay in discovery of inhibitors of beta-haematin crystallization, *Antimicrobial Agents and Chemotherapy* 55 (2011) 3363–3369.
- [39] F. Omodeo-Sale, L. Corteleszi, N. Basilico, M. Casagrande, A. Sparatore, D. Taramelli, Novel antimalarial aminoquinolines: heme binding and effects on normal or *Plasmodium falciparum*-parasitized human erythrocytes, *Antimicrobial Agents and Chemotherapy* 53 (2009) 4339–4344.
- [40] V. Thomas, A. Gois, B. Ritts, P. Burke, T. Hanscheid, G. McDonnell, A novel way to grow hemozoin-like crystals *in vitro* and its use to screen for hemozoin inhibiting antimalarial compounds, *Plos One* 7 (2012) e41006.
- [41] P.J. Rosenthal, Falcipains and other cysteine proteases of malaria parasites, *Advances in Experimental Medicine and Biology* 712 (2011) 30–48.
- [42] E.L. Dahl, P.J. Rosenthal, Biosynthesis, localization, and processing of falcipain cysteine proteases of *Plasmodium falciparum*, *Molecular and Biochemical Parasitology* 139 (2005) 205–212.
- [43] M.M.M. Santos, R. Moreira, Michael acceptors as cysteine protease inhibitors, *Mini Reviews in Medicinal Chemistry* 7 (2007) 1040–1050.
- [44] J.E. Olson, G.K. Lee, A. Semenov, P.J. Rosenthal, Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors, *Bioorganic & Medicinal Chemistry* 7 (1999) 633–638.
- [45] V. Sauvage, D. Aubert, A. Bonhomme, J.M. Pinon, J.M. Millot, P-glycoprotein inhibitors modulate accumulation and efflux of xenobiotics in extra and intracellular *Toxoplasma gondii*, *Molecular and Biochemical Parasitology* 134 (2004) 89–95.
- [46] S.A. Peel, The ABC transporter genes of *Plasmodium falciparum* and drug resistance, *Drug Resist Update* 4 (2001) 66–74.
- [47] A. Semenov, J.E. Olson, P.J. Rosenthal, Antimalarial synergy of cysteine and aspartic protease inhibitors, *Antimicrobial Agents and Chemotherapy* 42 (1998) 2254–2258.
- [48] J. Wiesner, D. Henschker, D.B. Hutchinson, E. Beck, H. Jomaa, *In vitro* and *in vivo* synergy of fosmidomycin, a novel antimalarial drug, with clindamycin, *Antimicrobial Agents and Chemotherapy* 46 (2002) 2889–2894.
- [49] A. Farnert, J. Lindberg, P. Gil, G. Swedberg, Y. Berqvist, M.M. Thapar, N. Lindegardh, S. Berezcky, A. Bjorkman, Evidence of *Plasmodium falciparum* malaria resistant to atovaquone and proguanil hydrochloride: case reports, *British Medical Journal* 326 (2003) 628–629.
- [50] M.A. Wijayanti, E.N. Sholikhah, R. Hadanu, J. Jumina, S. Supargiyono, M. Mustofa, Additive *in vitro* antiplasmodial effect of N-alkyl and N-benzyl-1,10-phenanthroline derivatives and cysteine protease inhibitor e64, *Malarial Research and Treatment* 2010 (2010). Article ID 540786, 8 pages.
- [51] L.M. Alcantara, J. Kim, C.B. Moraes, C.H. Franco, K.D. Franzoi, S. Lee, L.H. Freitas-Junior, L.S. Ayong, Chemosensitization potential of P-glycoprotein inhibitors in malaria parasites, *Experimental Parasitology* 134 (2013) 235–243.
- [52] W. Trager, J.B. Jensen, Human malaria parasites in continuous culture, *Science* 193 (1976) 673–675.
- [53] C. Lambros, J.P. Vanderberg, Synchronization of *Plasmodium falciparum* erythrocytic stages in culture, *The Journal of Parasitology* 65 (1979) 418–420.
- [54] S.P. Kumar, P.M.C. Gloria, L.M. Goncalves, J. Gut, P.J. Rosenthal, R. Moreira, M.M.M. Santos, Squaric acid: a valuable scaffold for developing antimalarials? *Medicinal Chemistry Communications* 3 (2012) 489–493.
- [55] S.D. Lucas, L.M. Goncalves, T.A.F. Cardote, H.F. Correia, R. Moreira, R.C. Guedes, Structure based virtual screening for discovery of novel human neutrophil elastase inhibitors, *Medicinal Chemistry Communications* 3 (2012) 1299–1304.
- [56] I.V. Tetko, J. Gasteiger, R. Todeschini, A. Mauri, D. Livingstone, P. Ertl, V. Palyulin, E. Radchenko, N.S. Zefirov, A.S. Makarenko, V.Y. Tanchuk, V.V. Prokopenko, Virtual computational chemistry laboratory - design and description, *Journal of Computer Aided Molecular Design* 19 (2005) 453–463.
- [57] S.H. Hilal, S.W. Karickhoff, L.A. Carreira, A rigorous test for SPARC's chemical reactivity models: estimation of more than 4300 ionization pK(a)s, *Quantitative Structure-Activity Relationship* 14 (1995) 348–355.
- [58] M. Charton, Electrical effects of *ortho*-substituents in pyridines and quinolines, *Journal of the American Chemical Society* 86 (1964) 2033–2037.
- [59] J. Clark, D.D. Perrin, Prediction of the strengths of organic bases, *Quantitative Reviews of the Chemical Society* 18 (1964) 295–320.